Weak Trigger
now
Phase 1 data for base-editing therapy 'VERVE-101' shows a single dose reduces LDL-C by up to 55% over a long-term follow-up period with zero severe adverse events.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |